• Es befinden sich keine Produkte im Warenkorb.


Literatur und weiterführende Links (FOOD 52-53)


Aagaard NK, Andersen H, Vilstrup H, Clausen T, Jakobsen J, Dørup I. Muscle strength, Na,K-pumps, magnesium and potassium in patients with alcoholic liver cirrhosis-relation to spironolactone. J Intern Med 2002; 252: 56-63.

Adams PC. Iron overload in viral and alcoholic liver disease. J Hepatol 1998; 28 Suppl 1: 19.

AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003; 125: 941–66.

Ahmed FE. Effect of diet on progression of chronic renal disease. J Am Diet Assoc. 1991; 91: 1266-1270.

Alberino F, Gatta A, Amodio P, et al. Nutrition and survival in patients with liver cirrhosis. Nutrition 2001; 17: 445–50.

Ali S, Hussain S, Hair M, Shah AA. Comparison of Maddrey Discriminant Function, Child-Pugh Score and Glasgow Alcoholic Hepatitis Score in predicting 28-day mortality on admission in patients with acute hepatitis. Ir J Med Sci 2013; 182: 63.

Alvares-da-Silva MR, Reverbel da Silveira T. Comparison between handgrip strength, subjective global assessment and prognostic nutritional index in assessing malnutrition and predicting outcome in cirrhotic outpatients. Nutrition 2005; 21: 113-7.

Amitrano L, Guardascione MA, Brancaccio V, et al. Coagulation disorders in liver disease. Semin Liver Dis 2002; 22: 83–96.

Anneren G, Magnusson CG, Nordvall SL. Increase in serum concentrations of IgG2 and IgG4 by selenium supplementation in children with Down’s syndrome. Arch Dis Child. 1990; 65: 1353–1355.

Aqel BA, Scolapio JS, Dickson RC, et al. Contribution of ascites to impaired gastric function and nutritional intake in patients with cirrhosis and ascites. Clin Gastroenterol Hepatol 2005; 3: 1095–10.

Araya J, Rodrigo R, Videla LA, et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond). 2004; 106: 635-643.

Arendt BM, Allard JP. Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: Is the combination required? Am J Gastroenterol. 2011; 106: 78-80.

Asbert M, Gines A, Gines P, et al. Circulating levels of endothelin in cirrhosis. Gastroenterology 1993; 104: 1485–91.

Assy N, Nasser G, Kamayse I, et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol. 2008; 22: 811-816.

Barton JC, McDonnell SM, Adams PC, et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998; 129: 932–9.

Bauer TM, Steinbruckner B, Brinkmann FE, Ditzen AK, Schwach H, Aponte JJ, et al. Small intestinal bacterial over growth in patients with cirrhosis: Prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol 2001; 96: 2962-7.

Bernardi M, Laffi G, Salvagnini M, et al. Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content. Liver 1993; 13: 156–62.

Bianchi GP, Marchesini G, Fabbri A, et al.Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross‑over comparison. J Intern Med 1993; 233: 385–92.

Blei AT, Larsen FS. Pathophysiology of cerebral edema in fulminant hepatic failure. J Hepatol 1999; 31: 771–776.

Bode C, Bode JC. Effect of alcohol consumption on the gut. Best Pract Res Clin Gastroenterol 2003; 17: 575.

Browning JD, Baker JA, Rogers T, Davis J, Satapati S, Burgess SC. Short-term weight loss and hepatic triglyceride reduction: Evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr. 2011; 93: 1048-1052.

Cabre E, Gassull MA. Nutrition in liver disease. Curr Opin Clin Nutr Metab Care 2005; 8: 545–51.

Campillo B, Richardet JP, Bories PN. Validation of body mass index for the diagnosis of malnutrition in patients with liver 131 cirrhosis. Gastroenterol Clin Biol 2006; 30: 1137-43.

Campillo B, Richardet JP, Scherman E, et al. Evaluation of nutritional practice in hospitalized cirrhotic patients: results of a prospective study. Nutrition 2003; 19: 515–21.

Charlton M. Branched‑chain amino‑acid granules: can they improve survival in patients with liver cirrhosis? Nat Clin Pract Gastroenterol Hepatol 2006; 3: 72–3.

Chaudhry V, Corse AM, O’Brian R, et al. Autonomic and peripheral (sensorimotor) neuropathy in chronic liver disease: a clinical and electrophysiologic study. Hepatology 1999; 29: 1698–703.

Chesta J, Defilippi C, Defilippi C. Abnormalities in proximal small bowel motility in patients with cirrhosis. Hepatology 1993; 17: 828–32.

Cheung AM. Post‑liver transplantation osteoporosis. J Hepatol 2001; 34: 337–8.

Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, ed. The liver and portal hypertension. Philadelphia: Saunders, 1964: 50–1.

Chojkier M, Houglum K, Lee KS, Buck M. Long- and short-term d-alpha-tocopherol supplementation inhibits liver collagen alpha1(I) gene expression. Am J Physiol. 1998; 275: G1480–G1485.

Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002; 50: Suppl 1:1–9.

Cook CC, Thomson AD. B-complex vitamins in the prophylaxis and treatment of Wernicke-Korsakoff syndrome. Br J Hosp Med 1997; 57: 461.

Cordoba J, Lopez-Hellin J, Planas M, Sabín P, Sanpedro F, Castro F, et al. Normal protein diet for episodic hepatic encephalopathy: Results of a randomized study. J Hepatol 2004; 41: 38-43.

Crawford D. Recent advances in malnutrition and liver disease. What’s New in Gastroenterology 1995; 48: 1-4.

Crawford DH, Leggett BA, Powell LW. Haemochromatosis. Baillieres Clin Gastroenterol 1998; 12: 209–225.

D’Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pres­sure gradient reduction and preven­tion of variceal bleeding in cirrhosis: a systematic review. Gastroenterolo­gy 2006; 131: 1611–1624.

D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognos­tic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217–231.

Dandona P, Aljada A, Bandyopadhyay A. Inflammation: The link between insulin resistance, obesity and diabetes. Trends Immunol. 2004; 25: 4-7.

Dekker MJ, Su Q, Baker C, Rutledge AC, Adeli K. Fructose: A highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome. Am J Physiol Endocrinol Metab. 2010; 299: E685-E694.

Detsky AS, Baker JP, Mendelson RA, Wolman SL, Wesson DE, Jeejeebhoy KN. Evaluating the accuracy of nutritional assessment techniques applied to hospitalized patients: Methodology and comparisons. J Parenter Enteral Nutr 1984; 8: 153-9.

Deutsche Leberholfe: Gemeinnütziger Verein, der bundesweit tätig ist und sich als Informationsschnittstelle zwischen Ärzten und Leberpatienten etabliert hat: http://www.leberhilfe.org/ (eingesehen am 02.11.2016)

Deutsche Forschungsgemeinschaft (DFG): Die Deutsche Forschungsgemeinschaft hat ein Sonderforschungsbereich „Leberentzündung: Infektion, Immunregulation und Konsequenzen“. Er wird als „SFB841“ bezeichnet und hat einen YouTube Kanal unter https://www.youtube.com/user/sfb841tv/featured(eingesehen am 11.01.2021)

Deutsche Gesellschaft für Neurologie. Leitlinie Alkoholdelir. Hamburg: Deutsche Gesellschaft für Neurologie, 2005.

DGE‑Stellungnahme. Vitaminversorgung in Deutschland. Forschung, Klinik und Praxis (2012): https://www.dge.de/wissenschaft/weitere-publikationen/stellungnahmen/ (eingesehen am 11.01.2021)

Duane P, Raja KB, Simpson RJ, Peters TJ. Intestinal iron absorption in chronic alcoholics. Alcohol Alcohol 1992; 27: 539.

Dudrick SJ, Kavic SM. Hepatobiliary nutrition: history and future. J Hepatobiliary Pancreat Surg 2002; 9: 459–68.

European Association for the Study of the Liver. EASL clinical prac­tice guidelines on the management of ascites, spontaneous bacterial pe­ritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397–417.

Ferenci P, Lockwood A et al. Hepatic encephalopathy – definition, nomenclature, diagnosis, and quan¬tification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna 1998. Hepatology 2002; 35: 716–721.

Figueiredo FA, Dickson ER, Pasha TM, et al. Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end‑stage liver disease. Liver Transplant 2000; 6: 575–81.

Fiore P, Merli M, Andreoli A, De Lorenzo A, Masini A, Ciuffa L, et al. A comparison of skinfold anthropometry and dualenergy x-ray absorptiometry for the evaluation of body fat in cirrhotic patients. Clin Nutr 1999; 18: 349-51.

Fleckenstein JF, Frank SM, Thuluvath PJ. Presence of autonomic neuropathy is a poor prognostic indicator in patients with advanced liver disease. Hepatology 1996; 23: 471–5.

Fletcher LM, Powell LW. Hemochromatosis and alcoholic liver disease. Alcohol 2003; 30: 131–136.

Fletcher LM. Alcohol and iron: One glass of red or more? J Gastroenterol Hepatol 1996; 11: 1039–1041.

Fodinger M, Sunder-Plassmann G. Inherited disorders of iron metabolism. Kidney Int Suppl 1999; 69: S22–S34.

Fonda ML, Brown SG, Pendleton MW. Concentration of vitamin B6 and activities of enzymes of B6 metabolism in the blood of alcoholic and nonalcoholic men. Alcohol Clin Exp Res 1989; 13: 804.

Fontanan RJ, Israel J, LeClair P, et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology. 2000; 31: 730–736.

Galati JS, Holdeman KP, Bottjen PL, et al. Gastric emptying and orocecal transit in portal hypertension and end-stage chronic liver disease. Liver Transpl Surg 1997; 3: 34–8.

Galati JS, Holdeman KP, Dalrymple GV, Harrison KA, Quigley E. Delayed Gastric Emptying of both the liquid and solid components of a meal in chronic liver disease. Am J Gastroenterol 1994; 89: 708-12.

Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141: 1572–1585.

Garg A, Bantle JP, Henry RR, et al. Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. JAMA. 1994; 271: 1421-1428.

Gauthier A, Levy VG, Quinton A, et al. Salt or no salt in the treatment of cirrhotic ascites: a randomized study. Gut 1986; 27: 705–9.

Geier A, Reugels M, Weiskirchen R, et al. Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C. Liver Int. 2004; 24: 285–294.

Gillingham LG, Harris-Janz S, Jones PJ. Dietary monounsaturated Fatty acids are protective against metabolic syndrome and cardiovascular disease risk factors. Lipids. 2011; 46: 209-228.

Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646–1654.

Gonzalez‑Calvin JL, Garcia‑Sanchez A, Bellot V, et al. Mineral metabolism, osteoblastic function and bone mass in chronic alcoholism. Alcohol 1993; 28: 571–9.

Guglielmi FW, Panella C, Buda A, et al. Nutritional state and energy balance in cirrhotic patients with or without hypermetabolism. Multicentre prospective study by the “Nutritional Problems in Gastroenterology” Section of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis 2005; 37: 681–8.

Halsted C, Keen CL. Alcoholism and micronutrient metabolism and deficiencies. Eur J Gastroenterol Hepatol 1990; 6: 399.

Harrison J, McKiernan J, Neuberger JM. A prospective study on the effect of recipient nutritional status on outcome in liver transplantation. Transpl Int 1997; 10: 369–74.

Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003; 98: 2485-2490.

Hauser RA, Zesiewicz TA. Manganese and chronic liver disease. Mov Disord 1996; 11: 589.

Häussinger D, Kircheis G, Fischer R et al. Hepatic encephalopathy in chronic liver disease: a clinical ma¬nifestation of astrocyte swelling and low-grade cereb¬ral edema. J. Hepatol 2000; 32: 1035–1038.

Henriksen JH, Bendtsen F, Gerbes AL, et al. Estimated central blood volume in cirrhosis: relationship to sympathetic nervous activity, beta‑adrenergic blockade and atrial natriuretic factor. Hepatology 1992; 16: 1163–70.

Hirsch S, de la Maza MP, Gattas V, et al. Nutritional support in alcoholic cirrhotic patients improves host defenses. J Am Coll Nutr 1999; 18: 434–41.

Hiyama DT, Fischer JE. Nutritional support in hepatic failure: the current role of disease-specific therapy. In: Fischer JE, editor. Total Parenteral Nutrition. 2nd Edition. Boston/Toronto/London: Little, Brown and Company; 1991. p. 263–78.

Homann C, Varming K, Hogasen K, et al. Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality. Gut 1997; 40: 544–9.

Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology. 1977; 113: 1069–1073.

Isobe H, Sakai H, Satoh M, et al. Delayed gastric emptying in patients with liver cirrhosis. Dig Dis Sci 1994; 39: 983–7.

Italian Multicentre Cooperative Project on nutrition in liver cirrhosis. Nutritional status in cirrhosis. J Hepatol 1994; 21: 317–25.

Jain SK, Pemberton PW, Smith A, et al. Oxidative stress in chronic hepatitis C: not just a feature of late-stage disease. J Hepatol. 2002; 36: 805–811.

Johnston CJ, Meyer CG, Srilakshmi JC. Vitamin C elevates red blood cell glutathione in healthy adults. Am J Clin Nutr. 1993; 58: 103–105.

Kaplan MM, Elta GH, Furie B, et al. Fat‑soluble vitamin nutriture in primary biliary cirrhosis. Gastroenterology 1988; 95: 787–92.

Kastorini CM, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB. The effect of Mediterranean diet on metabolic syndrome and its components: A meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol. 2011; 57: 1299-1313.

Kelly DA. Liver complications of pediatric parenteral nutrition–epidemiology. Nutrition 1998; 14: 153–157.

Khanna S, Gopalan S. Role of branched-chain amino acids in liver disease: the evidence for and against. Curr Opin Nutr Metab Care 2007; 10: 297-303.

Kircheis G, Häussinger D (2002) Management of hepatic encephalopathy. J Gastroenterol Hepatol 17.3: S260–S267.

Klasing KC. Effect of inflammatory agents and interleukin 1 on iron and zinc metabolism. Am J Physiol 1984; 247: R901–R904.

Knochel JP. The pathophysiology and clinical characteristics of severe hypophosphatemia. Arch Intern Med 1977; 137: 203.

Kollinger M, Kullmann F, Holstege A, et al. Prevention and therapy of complications of liver cirrhosis: ascites, encephalopathy and malnutrition. Med Klin 1996; 91: 89–102.

Kondrup J, Muller MJ. Energy and protein requirements of patients with chronic liver disease. J Hepatol 1997; 27: 239–47.

Kondrup J. Nutrition in end stage liver disease. Best Pract Res Clin Gastroenterol 2006; 20: 547–60.

Kowalski TE, Falestiny M, Furth E, et al. Vitamin A hepatotoxicity: a cautionary note regarding 25,000 IU supplements. Am J Med 1994; 97: 523–8.

Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003; 38: 413-419.

Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study. J Pediatr. 2000; 136: 734-738.

Layrargues GP, Rose C, Spahr L, Zayed J, Normandin L, Butterworth RF. Role of manganese in the pathogenesis of portal-systemic encephalopathy. Metab Brain Dis 1998; 13: 311–317.

Le KA, Ith M, Kreis R, et al. Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr. 2009; 89: 1760-1765.

Leevy CM, Moroianu SA. Nutritional aspects of alcoholic liver disease. Clin Liver Dis 2005; 9: 67.

Leevy CM. Thiamin deficiency and alcoholism. Ann N Y Acad Sci 1982; 378: 316.

Levy S, Herve C, Delacoux E, Erlinger S. Thiamine deficiency in hepatitis C virus and alcohol-related liver diseases. DigDis Sci 2002; 47: 543-8.

Lieber CS. Alcohol: Its metabolism and interaction with nutrients. Ann Rev Nutr 2000; 20: 395-430.

Liu Q, Duan ZP, Ha DK et al. (2004) Symbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 39: 1441–1449.

Lochs H, Plauth M. Liver cirrhosis: rationale and modalities for nutritional support – the European Society of Parenteral and Enteral Nutrition consensus and beyond. Curr Opin Clin Nutr Metab Care 1999; 2: 345–9.

Madden AM, Bradbury W,Morgam MY. Taste perception in cirrhosis: its relationship to circulating, micronutrients and food preferences. Hepatology 1997; 26: 40–8.

Manguso F, D’Ambra G, Menchise A, et al. Effects of an appropriate oral diet on the nutritional status of patients with HCV‑related liver cirrhosis: a prospective study. Clin Nutr 2005; 24: 751–9.

Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37: 917-923.

Marchesini G, Fabbri A, Bianchi G et al. Zinc supplementation and amino acid–nitrogen metabolism in patients with advanced cirrhosis. Hepatology 1996; 23: 1084–1092.

Markowitz JS, McRae AL, Sonne SC. Oral nutritional supplementation for the alcoholic patient: a brief overview. Ann Clin Psychiatry 2000; 12: 153.

Marsano L, McClain CJ. Nutrition and alcoholic liver disease. JPEN J Parenter Enteral Nutr 1991; 15: 337-44.

Martínez-Peinado M, Nogueras-López F, Arcos-Cebrián A, et al. Serum selenium levels in cirrhotic patients are not influenced by the disease severity index. Nutr Res. 2010; 30: 574–578.

Matos C, Porayko MK, Francisco‑Ziller N, et al. Nutrition and chronic liver disease. J Clin Gastroenterol 2002; 35: 391–7.

Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, Mc-Cullough AJ. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology. 1999; 116: 1413-1419.

McCullough AJ, Bugianesi E. Protein‑calorie malnutrition and the etiology of cirrhosis. Am J Gastroenterol 1997; 92: 734–8.

McCullough AJ, Mullen KD, Kalhan SC. Measurements of total body and extracellular water in cirrhotic patients with and without ascites. Hepatology 1991; 14: 1102–11.

McLaughlin T, Abbasi F, Lamendola C, Yeni-Komshian H, Reaven G. Carbohydrate-induced hypertriglyceridemia: an insight into the link between plasma insulin and triglyceride concentrations. J Clin Endocrinol Metab. 2000; 85: 3085-3088.

Mendenhall CL, Anderson S, Weesner RE, Goldberg SJ, Crolic KA. Protein-calorie malnutrition associated with alcoholic hepatitis. Am J Med 1984; 76: 211-22.

Merli M, Nicolini G, Angeloni S, et al. Malnutrition is a risk factor in cirrhotic patients undergoing surgery. Nutrition 2002; 18: 978–86.

Mikkelsen PB, Toubro S, Astrup A. Effect of fat-reduced diets on 24-h energy expenditure: Comparisons between animal protein, vegetable protein, and carbohydrate. Am J Clin Nutr. 2000; 72: 1135-1141.

Miller ER, 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005; 142: 37-46.

Mobarhan SA, Russell RM, Recker RR, Posner DB, Iber FL, Miller P. Metabolic bone disease in alcoholic cirrhosis: A comparison of the effect of vitamin D2, 25-hydroxyvitamin D of supportive treatment. Hepatology 1984; 4: 266-73.

Morgan AG, Kelleher J, Walker BE, et al. Nutrition in cryptogenic cirrhosis and chronic aggressive hepatitis. Gut 1976; 17: 113–8.

Morgan MY. Enteral nutrition in liver disease. Acta Chir Scand 1981; 507: Suppl: 81–91.

Moschen AR, Kaser A, Stadlmann S, et al. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol 2005; 43: 973–83.

Müller MJ, Fenk A, Lautz HU, et al. Energy expenditure and substrate metabolism in ethanol‑induced liver cirrhosis. Am J Physiol 1991; 260: E338–44.

Müller MJ, Lautz HU, Plogmann B, et al. Energy expenditure and substrate oxidation in patients with cirrhosis: the impact of cause, clinical staging and nutritional state. Hepatology 1992; 15: 782–94.

Müller MJ, Selberg O, Böker K. Are patients with liver cirrhosis hypermetabolic? Clin Nutr 1994; 13: 131–44.

Müller MJ, Westenhöfer J, Bosy-Westphal A, et al. Ernährungsmedizinische Untersuchungen. In: Müller MJ, Hrsg. Ernährungsmedizinische Praxis: Methoden – Prävalenz – Behandlung, 2. Aufl. Berlin–Heidelberg: Springer, 2007: 78–92.

Müller MJ. Ernährung von Leberkranken. In: Schmidt E, Schmidt FW, Manns MP, Hrsg. Lebererkrankungen. Pathophysiologie – Diagnostik – Therapie. Stuttgart: Wiss. Verl.‑Ges., 2000: 1080–104.

Muller MJ, Boker KH, Selberg O. Are patients with liver cirrhosis hypermetabolic? Clin Nutr 1994; 13: 131-44.

Murakami Y, Koyabu T, Kawashima A, et al. Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin. J Nutr Sci Vitaminol (Tokyo). 2007; 53: 213–218.

Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003; 37: 909-916.

Muto Y, Sato S, Watanabe A, et al., Long‑Term Survival Study Group. Effects of oral branched‑chain amino acid granules on event‑free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005; 3: 705–13.

Newsome PN, Beldon I, Moussa Y, Delahooke TE, Poulopoulos G, Hayes PC, et al. Low serum retinal levels are associated with hepatocellular carcinoma in patients with chronic liver disease. Aliment Pharmacol Ther 2000; 14: 1295-301.

Ng VL, Balistreri WF. Treatment options for chronic cholestasis in infancy and childhood. Curr Treat Options Gastroenterol 2005; 8: 419–30.

Niederau C, Hermann T, Strohmeyer G. Hereditäre Hämochromatose. In: Strohmeyer G, Stremmel W, Niederau C, Hrsg. Angeborene Stoffwechselerkrankungen. Landsberg: Ecomed, 2002: 121–55.

Nompleggi DJ, Bonkovsky HL. Nutritional supplementation in chronic liver disease: an analytical review. Hepatology 1994; 19: 518–33.

Norman K, Kirchner H, Lochs H, et al. Malnutrition affects quality of life in gastroenterology patients. World J Gastroenterol 2006; 12: 3380–5.

O’Brien A, Williams R. Nutrition in end-stage liver disease: principles and practice. Gastroenterology 2008; 134: 1729–40.

Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008; 48: 993-999.

Panagiotakos DB, Polychronopoulos E. The role of Mediterranean diet in the epidemiology of metabolic syndrome; converting epidemiology to clinical practice. Lipids Health Dis. 2005; 4: 7.

Petrides AS, DeFronzo RA. Glucose metabolism in cirrhosis: a review with some perspective for the future. Diabetes Metab Rev 1989; 5: 691–709.

Phillips JR, Angulo P, Petterson T, Lindor KD. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001; 96: 2745-50.

Pikul J, Sharpe MD, Lowndes R, Ghent CN. Degree of preoperative malnutrition is predictive of postoperative morbidity and mortality in liver transplant recipients. Transplantation 1994; 57: 469-72.

Pirlich M, Lochs H, Ockenga J. Enteral nutrition. Internist (Berl) 2006; 47: 405–22.

Pirlich M, Norman K, Lochs H. Malnutrition in liver cirrhosis: impact of protein rich oral diet. Z Gastroenterol 2006; 44: 344–5.

Pitts TO, Van Thiel DH. Disorders of divalent ions and vitamin D metabolism in chronic alcoholism. Recent Dev Alcohol 1986; 4: 357.

Plauth M, Cabre E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J; et al. ESPEN guidelines on enteral nutrition: Liver disease. Clin Nutr 2006; 25: 285-94.

Plauth M, Ferenci P, Holm E, et al. DGEM‑Leitlinie Enterale Ernährung: Hepatologie. Akt Ernaehr Med 2003; 28: Suppl 1: S87–92.

Plauth M, Merli M, Kondrup J, et al. ESPEN guidelines for nutrition in liver disease and transplantation. Clin Nutr 1997; 16: 43–55.

Plauth M, Weimann A, Holm E, et al. Guidelines of GASL for nutrition in liver diseases and liver transplantation. Z Gastroenterol 1999; 37: 301–12.

Plauth M. Branched chain amino acids as oral supplements in liver cirrhosis. Z Gastroenterol 2006; 44: 207–8.

Prakash R, Mullen KD. Mecha­nisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010; 7: 515–525.

Quigley EM. Gastrointestinal dysfunction in liver disease and portal hypertension. Dig Dis Sci 1996; 41: 557–61.

Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy: Results of a randomized controlled trial. Lancet 1984; 2: 493-4.

Reynolds TB, Lieberman FL, Goodman AR. Advantages of treatment of ascites without sodium restriction and without complete removal of excess fluid. Gut 1978; 19: 549–53.

Rigamonti C, Andorno S, Maduli E, et al. Gender and liver fibrosis in chronic hepatitis: the role of iron status. Aliment Pharmacol Ther. 2005; 21: 1445–1451.

Riggio O, Ariosto F, Merli M, Caschera M, Zullo A, Balducci G, et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy: Results of a double-blind crossover trial. Dig Dis Sci 1991; 36: 1204-8.

Riordan S, Williams R. Treatment of hepatic encephalopathy. NEJM 1997; 337: 473–478.

Roonpisuthipong C, Sobhonslidsuk A, Nantiruj K, et al. Nutritional assessment in various stages of liver cirrhosis. Nutrition 2001; 17: 761–5.

Ryan MC, Abbasi F, Lamendola C, Carter S, McLaughlin TL. Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults. Diabetes Care. 2007; 30: 1075-1080.

Sakaida I, Tsuchiya M, Okamoto M, et al. Late evening snack and the change of blood glucose level in patients with liver cirrhosis. Hepatol Res 2004; 30S: 67–72.

Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362: 1675-1685.

Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004; 2: 1107-1115.

Sarin SK, Dhingra N, Bansal A, et al. Dietary and nutritional abnormalities in alcoholic liver disease: a comparison with chronic alcoholics without liver disease. Am J Gastroenterol 1997; 92: 777–83.

Sathiaraj E, Chutke M, Reddy MY, et al. A case-control study on nutritional risk factors in non-alcoholic fatty liver disease in Indian population. Eur J Clin Nutr. 2011; 65: 533-537.

Schenker S, Halff GA. Nutritional therapy in alcoholic liver disease. Semin Liver Dis 1993; 13: 196–209.

Schiefke I, Fach A, Wiedmann M, et al. Reduced bone mineral density and altered bone turnover markers in patients with non‑cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 2005; 11: 1843–7.

Scholmerich J, Becher MS, Kottgen E, et al. The influence of portosystemic shunting on zinc and vitamin A metabolism in liver cirrhosis. Hepatogastroenterology 1983; 30: 143–7.

Scholmerich J, Fabian M, Tauber R, et al. Portacaval shunt as an experimental model of impaired hepatic release of vitamin A in liver disease. Gastroenterology 1991; 100: 1379–84.

Schoonjans R, Van Vlem B, Vandamme W, et al. Gastric emptying of solids in cirrhotic and peritoneal dialysis patients: influence of peritoneal volume load. Eur J Gastroenterol Hepatol 2002; 14: 395–8.

Sechi G, Serra A. Wernicke’s encephalopathy: New clinical settings and recent advances in diagnosis and management. Lancet Neurol 2007; 6: 442-55.

Selberg O, Bottcher J, Tusch G, et al. Identification of high‑ and low‑risk patients before liver transplantation: a prospective cohort study of nutritional and metabolic parameters in 150 patients. Hepatology 1997; 25: 652–7.

Selberg O, Müller MJ. Ernährungsmedizinische Untersuchungen. In: Müller MJ, Hrsg. Ernährungsmedizinische Praxis: Methoden – Prävalenz – Behandlung. Berlin–Heidelberg: Springer, 1998: 301.

Shimizu N, Yamaguchi Y, Aoki T. Treatment and management of Wilson’s disease. Pediatr Int 1999; 41: 419–22.

Sintrin MD, Bengoa JM. Intestinal absorption of cholecalciferol and 25‑hydroxycholecalciferol in chronic cholestatic liver disease. Am J Clin Nutr 1987; 46: 1011–15.

Snover DC. Hepatitis C, iron, and hemochromatosis gene mutations. A meaningful relationship or simple cohabitation? Am J Clin Pathol 2000; 113: 475–478.

Sokol RJ. Fat-soluble vitamins and their importance in patients with cholestatic liver diseases. Gastroenterol Clinics N Am 1994; 23: 673-705.

Solga S, Alkhuraishe AR, Clark JM, et al. Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci. 2004; 49: 1578-1583.

Soulsby CT, Morgan MY. Dietary management of hepatic encephalopathy in cirrhotic patients: survey of current practice in United Kingdom. BMJ 1999; 31: 95–103.

Souza dos Santos RM, de Bem AF, Colpo E, et al. Plasmatic vitamin C in nontreated hepatitis C patients is negatively associated with aspartate aminotransferase. Liver Int. 2008; 28: 54–60.

Spahr L, Burkhard PR, Grotzsch H, Hadengue A. Clinical significance of basal ganglia alterations at brain MRI and 1H MRS in cirrhosis and role in the pathogenesis of hepatic encephalopathy. Metab Brain Dis 2002; 17: 399–413.

Spahr L, Butterworth RF, Fontaine S, Bui L, Therrien G, Milette PC, Lebrun LH, Zayed J, Leblanc A, Pomier-Layrargues G. Increased blood manganese in cirrhotic patients: Relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms. Hepatology 1996; 24: 1116–1120.

Stellon AJ, Webb A, Compston JE. Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis. Gut 1988; 29: 378–84.

Swart GR, van den Berg JW, van Vuure JK, et al. Minimum protein requirements in liver cirrhosis determined by nitrogen balance measurements at three levels of protein intake. Clin Nutr 1989; 8: 329–36.

Swart GR, Van den Berg JWO, Wattimena JL, et al. Elevated protein requirements in cirrhosis of the liver investigated by whole body protein turnover studies. Clin Sci (Lond) 1988; 75:101–7.

Tapsell LC, Gillen LJ, Patch CS, et al. Including walnuts in a low-fat/ modified-fat diet improves HDL cholesterol-to-total cholesterol ratios in patients with type 2 diabetes. Diabetes Care. 2004; 27: 2777-2783.

Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346: 987–990.

Temmel AF, Pabinger S, Quint C, et al. Dysfunction of the liver affects the sense of smell. Wien Klin Wochenschr 2005; 117: 26–30.

Testa R, Franceschini R, Giannini E, Cataldi A, Botta F, Fasoli A, et al. Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis. J Hepatol 2000; 33: 33-7.

Thomson AD, Jeyasingham MD, Pratt OE, Shaw GK. Nutrition and alcoholic encephalopathies. Acta Med Scand Suppl 1987; 717: 55.

Thuluvath PJ, Triger DR. Autonomic neuropathy and chronic liver disease. Q J Med 1989; 72: 737–47.

Thuluvath PJ, Triger DR. How valid are our reference standards of nutrition? Nutrition 1995; 11: 731-3.

Tsuchiya M, Sakaida I, Okamoto M, et al. The effect of a late evening snack in patients with liver cirrhosis. Hepatol Res 2005; 31: 95–103.

Uribe M, Dibildox M, Malpica S, et al. Beneficial effect of vegetable protein diet supplemented with psyllium plantago in patients with hepatic encephalopathy and diabetes mellitus. Gastroenterology 1985; 88: 901–7.

Vallim T, Salter AM. Regulation of hepatic gene expression by saturated fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2010; 82: 211-218.

Van der Rijt CC, Schalm SW, Schat H, Foeken K, De Jong G. Overt hepatic encephalopathy precipitated by zinc deficiency. Gastroenterology 1991; 100: 1114–1118.

Vech RL, Lumeng L, Li TK. Vitamin B6 metabolism in chronic alcohol abuse The effect of ethanol oxidation on hepatic pyridoxal 5′-phosphate metabolism. J Clin Invest 1975; 55: 1026.

Vilar L, Oliveira CP, Faintuch J, et al. High-fat diet: A trigger of nonalcoholic steatohepatitis? Preliminary findings in obese subjects. Nutrition. 2008; 24: 1097-1102.

Vonnahme EJ, Schmidt H. Hämatologische Veränderungen bei chronischen Lebererkrankungen. In: Schmidt E, Schmidt FW, Manns MP, Hrsg. Lebererkrankungen. Pathophysiologie – Diagnostik – Therapie. Stuttgart: Wiss. VerlGes, 2000: 1108–11.

Waggoner DJ, Bartnikas TB, Gitlin JD. The role of copper in neurodegenerative disease. Neurobiol Dis 1999; 6: 221–230.

Wei-Kuo C, You-Chen C, Hung-Shang T, Hui-Fen L, Chung- Te H. Effects of extra-carbohydrate supplementation in the late evening on energy expenditure and substrate oxidation in patients with liver cirrhosis. JPEN J Parenter Enteral Nutr 1997; 21: 96-9.

Wettstein M, Kircheis G, Häussinger D. Hepatische Enzephalopathie – Diagnostik. Dtsch Med Wochenschr 2003; 128: 2654–7.

Yamamoto M, Iwasa M, Iwata K, et al. Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2007; 22: 498-503.

Yang SS, Lai YC, Chiang TR, et al. Role of zinc in subclinical hepatic encephalopathy: comparison with somatosensory‑evoked potentials. J Gastroenterol Hepatol 2004; 19: 375–9.

Yu MW, Horng IS, Hsu KH, et al. Plasma selenium levels and risk for hepatocellular carcinoma among men with chronic hepatitis virus infection. Am J Epidemiol. 1999; 150: 367–374.

Yu SY, Zhu YJ, Li WG. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol Trace Elem Res. 1997; 56: 117–124.

Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): A population based study. J Hepatol. 2007; 47: 711-717.

Pharmabrain Logo

European Union Trademark no. 006894216
US Patent and Trademark Office reg. no. 3,705,613
International Registration 1460744
All rights reserved.

Wir sind Pharmabrain.

Pharmabrain GmbH – Wir trainieren Ihren Erfolg
Gesundheitskommunikation, Teamentwicklung, Projektmanagement


Pharmabrain GmbH
Telefon: +49-30-28091515
E-Mail: support@pharmabrain.org

Research and Training Center

Schumannstr. 7b
D-10117 Berlin


Schumannstr. 7a
D-10117 Berlin